Skip to main content

Table 1 General characteristics of patients in the two groups

From: α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study

Parameters

Control (n = 19)

Miglitol-treated (n = 18)

P value

Men (%)

15 (79)

16 (89)

0.659

Age (years)

63 (13)

62 (12)

0.855

Body weight (kg)

69.9 (13.8)

70.9 (15.7)

0.855

Body mass index (kg/m2)

26.2 (4.7)

25.3 (4.3)

0.536

Systolic blood pressure (mmHg)

119 (20)

116 (19)

0.665

Diastolic blood pressure (mmHg)

68 (10)

67 (10)

0.866

Heart rate (beats/min)

75 (14)

76 (10)

0.794

Left ventricular ejection fraction (%)

53 (13)

54 (10)

0.760

Fasting plasma glucose (mmol/L)

7.94 (2.94)

7.83 (1.78)

0.870

HbA1c (%)

6.5 (1.1)

6.8 (0.9)

0.357

HbA1c (mmol/mol)

47.5 (11.5)

50.8 (13.7)

0.357

1,5-anhydro-d-glucitol (µg/mL)

16.0 (10.5)

12.3 (8.1)

0.240

Total cholesterol (mmol/L)

4.55 (0.93)

4.91 (1.19)

0.329

LDL cholesterol (mmol/L)

2.74 (0.75)

2.92 (0.93)

0.534

HDL cholesterol (mmol/L)

1.19 (0.34)

1.32 (0.36)

0.300

Triglyceride (mmol/L)

1.35 (0.61)

1.47 (0.98)

0.673

Non-HDL cholesterol (mmol/L)

3.36 (0.85)

3.59 (1.19)

0.528

Creatinine (µmol/L)

73.4 (17.7)

75.1 (18.6)

0.751

  1. Values are mean (SD) or n (%)
  2. LDL low-density lipoprotein, HDL high-density lipoprotein